Fresh analysis suggests that individuals who stop using new GLP-1 drugs like Mounjaro or Wegovy tend to recover shed pounds much more quickly than those who stop traditional diet and exercise regimens.
Research printed in a leading health publication demonstrates that while obese people frequently drop a large proportion of their total mass while on the medication, the mass is regained at an estimated rate of 0.8 kg per month once they quit.
"Individuals buying such medications need to be informed of the danger of quick rebound weight gain when the medication is stopped," cautioned expert Dr. Susan Jebb.
Such speed of regain implies a reversion to pre-treatment weight within about a year and a half.
Weighing Approaches
The study, which reviewed dozens of trials involving over 9,000 of participants, contrasted the results of GLP-1 agonists with older methods.
Researchers point out that individuals who shed pounds through diet and exercise typically see a slower creep back—approximately 0.1 kg a month—once they finish.
Understanding the Rapid Regain
Nutrition scientists believe the mechanism of the drugs is key to understanding the accelerated regain.
These medications copy a natural hormone called glucagon-like peptide-1, which helps regulate hunger.
"Artificially providing the hormone levels several times higher than normal could lead to the system to generate a reduced amount of its endogenous GLP-1, and may also lessen sensitivity to its actions," noted Dr. Adam Collins, a nutrition specialist.
"Discontinuation of this GLP-1 'fix' leads to appetite is unsuppressed, making binge eating a significant risk."
A Chronic Issue?
Health authorities recommend the injections for individuals with obesity-related health risks, alongside recommended diet and exercise modifications.
Many experts argue that, due to the significant potential of weight regain, the treatment should be considered life-long.
This view is supported by drug manufacturers, who note that the results "highlight the chronic character of obesity," similar to managing diseases like hypertension.
Patient Testimonies
Individuals who have come off the jabs describe a intense resurgence of hunger.
"I experienced a switch flipping and I was suddenly extremely hungry," said an individual.
This difficulty is worsened if individuals have not developed lasting dietary or behavioural changes during therapy.
Widespread Interest
Figures show that millions of people in the UK have used weight-loss jabs in the last 12 months, with desire continuing to grow.
- Adoption is greater among females compared to males.
- The 40s and 50s demographic shows the greatest level of interest.
- A large proportion access the medications through private healthcare rather than public health services.
In conclusion, clinicians caution that while these medications are powerful tools for shedding pounds, they are not a magic fix and long-term success hinges on combined lifestyle management.